Corvus Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Corvus Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 2 currently recruiting 6 completed early-phase tilt top decile by trial count

Corvus Pharmaceuticals: 10 sponsored US clinical trials, 2 recruiting.

Corvus Pharmaceuticals sponsors 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atopic Dermatitis, with 2 trials.

Top-decile sponsor footprint

Corvus Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

NCT07441395
RECRUITING Phase 3

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

NCT06561048
ACTIVE NOT RECRUITING Phase 1

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

NCT03952078
COMPLETED Phase 1

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

NCT06345404
TERMINATED Phase 3

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

NCT04734873
COMPLETED Phase 1

Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

NCT04464395
COMPLETED Phase 1

Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

NCT04280328
COMPLETED Phase 1

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

NCT03454451
COMPLETED Phase 1

Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects

NCT03237988
COMPLETED Phase 1

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

NCT02655822

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 1
Phase 3 2

Therapeutic Areas

Atopic Dermatitis 2
Eczema, Atopic 1
Lymphoma, T-Cell, Peripheral 1
Systemic Anaplastic Large Cell Lymphoma 1
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype 1
Follicular T-Cell Lymphoma 1
Angioimmunoblastic T-cell Lymphoma 1
Lymphoma, T-Cell 1
Peripheral T-Cell Lymphoma, Not Otherwise Specified 1
T-Cell Lymphoma 1

What is open in the Corvus Pharmaceuticals pipeline

2 recruiting of 10 indexed (20% open); 6 completed (60%).

Phase mix: 2 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Atopic Dermatitis (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Corvus Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 10 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

Corvus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4681012 0%10%20%30%40% Total trials Recruiting share Corvus PharmaceuticalsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAcera SurgicalAlign TechnologyAltruBioAlvernia University
Corvus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Corvus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Corvus Pharmaceuticals page

10 registered trials is a research-attention snapshot, not an endorsement of Corvus Pharmaceuticals or any single study.

  • 2 of Corvus Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Atopic Dermatitis is the condition Corvus Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atopic Dermatitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Corvus Pharmaceuticals pipeline card: 10 registered trials from official public datasets.Report a data error.